Oral GLP-1 Pill Orforglipron Posts Strong Phase 3 Results in Adults With Type 2 Diabetes
Eli Lilly recently shared excellent news about a novel medication. The company tested the investigational drug orforglipron in extensive…
-
-
Orforglipron Surges Ahead: Eli Lilly’s Oral GLP-1 Pill Beats Oral Semaglutide in Landmark Diabetes Trial
Eli Lilly has unveiled striking results from a head-to-head clinical trial showing its experimental oral GLP-1 pill, Orforglipron, outperformed…
-
Oral Semaglutide Found Cost-Saving Over Dulaglutide for Type 2 Diabetes in Taiwan, Study Shows
A new economic analysis finds that oral semaglutide may save money and improve outcomes for patients with type 2…
-
Lilly Bets Big on Obesity Pill, Leaving Peptron Deal in Limbo
Eli Lilly and Company is accelerating its push into the fast-growing obesity drug market. However, its renewed focus on…
-
SNAC Under the Microscope: Study Questions Safety of Key Ingredient in Oral Weight-Loss Pills
A new study has placed salcaprozate sodium, known as SNAC, under scientific scrutiny. Researchers warn that this widely used…
-
Eli Lilly Stock Jumps as $1.5 Billion Weight-Loss Pill Nears Market Launch
Shares of Eli Lilly and Company moved higher this week after the drugmaker signaled strong confidence in its upcoming…
-
Wegovy Pill Draws Wave of First-Time Users, Expanding GLP-1 Weight-Loss Market
More than a third of patients who started taking Novo Nordisk’s Wegovy pill had never used a GLP-1 drug…
-
From Needles to Pills: Big Pharma’s High-Stakes Race to Redefine Weight Loss
Pharmaceutical companies are racing to transform weight‑loss treatment. They are shifting from weekly injections to daily pills, opening easier…
-
Magnum Bets on Bite-Sized Indulgence as Weight-Loss Jabs Reshape Snacking Habits
The chief executive of The Magnum Ice Cream Company says weight-loss jabs could create new growth for premium ice…
-
Eli Lilly’s GLP-1 Surge Gains Speed as Orforglipron and Orna Deal Power Next Growth Wave
Eli Lilly and Company continues to build strong momentum in the fast-growing GLP-1 drug market. The company is expanding…
